Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year.

Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. This illness often begins with little or no symptoms, meaning patients and their doctors discover it when it’s too late for preventative treatment. Conducting successful ovarian cancer clinical trials can help us uncover new treatments and save lives — but…